![\"\"](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/08\/Celadon_Pharmaceuticals_Plc_logo.png\"){kind=logo}
<\/p>\n
\u00a0<\/p>\n
UK medical cannabis cultivator Celadon Pharmaceuticals has voted to delist its shares from public trading, following months of financial turmoil and funding woes.<\/p>\n
In a statement issued on 1 July,<\/a> the company announced plans to cancel the admission of its ordinary shares trading on AIM effective 8 August, pending shareholder approval at a general meeting on 28 July.<\/p>\n At the time, the company said: \u201cThe Chief Executive Officer of the Company believes the proposed cancellation\u2026 to be in the best interests of the Company and its shareholders.\u201d<\/p>\n In a market statement on August 08, Celadon confirmed that shareholders had voted to approve this action, which will now see the company reregister as a private entity.<\/p>\n In a separate statement, Celadon also confirmed that Chair Alexander Anton has resigned from his position effective immediately<\/a>, leaving just CEO James Short on the board. This comes after more than 40% of shareholders voted against his re-election at its recent AGM.<\/p>\n Celadon\u2019s delisting marks the latest in a string of British cannabis and biotech firms to exit in recent months, marking an increasing trend towards private investment.<\/p>\n Asked about this emerging trend, and whether we could see the few remaining European-listed cannabis companies follow suit, Anthony Coniglio, co-founder and CEO of NewLake Capital Partners<\/a>, and one of the industry\u2019s leading voices on cannabis capital markets and regulatory strategy, told Business of Cannabis that many companies simply had no choice.<\/p>\n \u201cThey\u2019d love to save the money and go private, but their options are very limited. Yes, they could de-list, but with a large shareholder base they\u2019d still need much of the same apparatus to communicate with those investors.<\/p>\n \u201cThis isn\u2019t a \u2018go private\u2019 scenario where a private equity firm buys the company, takes it off the market, and you can dismantle your investor relations team because you only have a handful of investors. That\u2019s not the case here \u2014 there\u2019s simply no capital available to take these companies private.<\/p>\n \u201cWith delisting, you also have to navigate approval requirements, and you risk angering shareholders who are suddenly left with no liquidity \u2014 even if the stock\u2019s performance hasn\u2019t been great.\u201d<\/p>\n \u201cManagement teams are going to hesitate before going private if there\u2019s any chance of a catalyst that could send their stock price soaring.<\/p>\n \u201cOne unknown is how MSOs fit into this. Many own stakes in these companies, but I\u2019m not sure if they could legally own private entities. You\u2019d have to dig into the rules \u2014 and even then, how would they unwind their positions?\u201d<\/p>\n SEED Innovations\u00a0<\/strong><\/p>\n \u00a0<\/p>\n SEED Innovations has become the latest cannabis company<\/a> to announce plans to shift its focus away from the industry towards the emerging artificial intelligence sector.<\/p>\n In a circular published on July 18, the AIM-listed investment firm, which has until now largely focused its strategy on cannabis and biotech ventures, unveiled its plans for a major strategic pivot.<\/p>\n The announcement came alongside proposals for a Tender Offer to buy back up to 45% of its issued share capital, providing an off-market exit at a premium to recent share prices.<\/p>\n Both will be put to a vote at SEED\u2019s upcoming Annual General Meeting (AGM) on August 13, 2025.<\/p>\n This shift follows a challenging 2024<\/a> and increased involvement from former chairman Jim Mellon, who has now grown his stake in the company to over 20%.<\/p>\n Mellon is set to rejoin the board alongside Denham Eke, replacing outgoing CEO Ed McDermott and executive Alfredo Pascual, both of whom will support the transition over the coming months.<\/p>\n The new direction is a marked change from the company\u2019s position in January, when McDermott described 2024 as \u2018difficult,\u2019 but reiterated SEED\u2019s \u2018industry-agnostic trading strategy\u2019 and pointed to \u2018promising\u2019 investment opportunities across various sectors.<\/p>\n At the time, he highlighted a capital gap facing early-stage ventures but remained optimistic about backing scalable companies capable of delivering meaningful exits within 24 months.<\/p>\n Synbiotic SE<\/strong><\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n As the German medical cannabis market reels from threats of a clampdown on telehealth prescribing, a major driver of growth in the flourishing market, multi-brand operator Synbiotic SE has assured investors of its solid market position.<\/p>\n In a market update from July 29<\/a>, CEO Daniel Kruse said the group\u2019s strategy offers investors exposure to \u2018two billion-euro growth\u2019 markets, including both medical cannabis and industrial hemp.<\/p>\n![\"\"](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/08\/download-3.webp.webp\")
<\/p>\n![\"\"](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/08\/619eb4aced3413505da3ee38_synbiotic-logo.webp.webp\"){kind=logo}
<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/08\/cantourage_0b9d7335-063e-4240-b4d4-804289ec11c5.webp.webp\")
<\/p>\n